Free Trial

Zymeworks (ZYME) Stock Price, News & Analysis

Zymeworks logo
$14.71 -0.13 (-0.89%)
As of 02:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Zymeworks Stock (NYSE:ZYME)

Key Stats

Today's Range
$14.68
$15.09
50-Day Range
$12.02
$15.10
52-Week Range
$9.03
$17.70
Volume
156,834 shs
Average Volume
525,973 shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.43
Consensus Rating
Moderate Buy

Company Overview

Zymeworks Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ZYME MarketRank™: 

Zymeworks scored higher than 46% of companies evaluated by MarketBeat, and ranked 838th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zymeworks has only been the subject of 2 research reports in the past 90 days.

  • Read more about Zymeworks' stock forecast and price target.
  • Earnings Growth

    Earnings for Zymeworks are expected to decrease in the coming year, from ($1.39) to ($1.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zymeworks is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zymeworks is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zymeworks has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zymeworks' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ZYME.
  • Dividend Yield

    Zymeworks does not currently pay a dividend.

  • Dividend Growth

    Zymeworks does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ZYME.
  • News Sentiment

    Zymeworks has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • Search Interest

    2 people have searched for ZYME on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Zymeworks to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zymeworks insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.92% of the stock of Zymeworks is held by insiders.

  • Percentage Held by Institutions

    92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zymeworks' insider trading history.
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZYME Stock News Headlines

Zymeworks Reports Q2 Results and FDA Clearance
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
See More Headlines

ZYME Stock Analysis - Frequently Asked Questions

Zymeworks' stock was trading at $14.64 at the beginning of the year. Since then, ZYME stock has increased by 1.1% and is now trading at $14.8050.

Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings data on Thursday, August, 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.52) by $0.55. Zymeworks's revenue for the quarter was up 153.2% compared to the same quarter last year.

Zymeworks (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Zymeworks' top institutional investors include EcoR1 Capital LLC (30.56%), Rubric Capital Management LP (6.27%), Redmile Group LLC (5.52%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.93%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Paul Andrew Moore, Neil Josephson, Jeffrey T L Smith and Christopher Astle.
View institutional ownership trends
.

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/07/2025
Today
8/29/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ZYME
Previous Symbol
NASDAQ:ZYME
CIK
1937653
Employees
460
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$13.00
Potential Upside/Downside
+45.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.67 million
Net Margins
-182.75%
Pretax Margin
-189.75%
Return on Equity
-23.00%
Return on Assets
-18.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.10
Quick Ratio
4.10

Sales & Book Value

Annual Sales
$122.87 million
Price / Sales
9.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.63 per share
Price / Book
2.22

Miscellaneous

Outstanding Shares
75,166,000
Free Float
67,556,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
1.26

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:ZYME) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners